Dr. Ibiayi Dagogo-Jack, MD
Claim this profileMassachusetts general Hospital
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
9 reported clinical trials
17 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage III
ALK positive
2Non-Small Cell Lung Cancer
Stage IV
Stage III
ALK positive
Affiliated Hospitals
Clinical Trials Ibiayi Dagogo-Jack, MD is currently running
IAG933
for Mesothelioma
This trial tests a new drug called IAG933 in patients with specific types of tumors. It aims to find the safest and most effective dose and see if the drug can help shrink the tumors.
Recruiting1 award Phase 114 criteria
LY4050784
for Advanced Cancer
The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two parts - phase Ia (dose-escalation) and phase Ib (dose-optimization, dose-expansion). The study will last up to approximately 4 years.
Recruiting1 award Phase 12 criteria
More about Ibiayi Dagogo-Jack, MD
Clinical Trial Related4 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Ibiayi Dagogo-Jack, MD has experience with
- Pembrolizumab
- Lorlatinib
- Alectinib
- Cobimetinib
- IAG933
- Anetumab Ravtansine
Breakdown of trials Ibiayi Dagogo-Jack, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Malignant Pleural Mesothelioma
Mesothelioma
Uterine Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ibiayi Dagogo-Jack, MD specialize in?
Ibiayi Dagogo-Jack, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Ibiayi Dagogo-Jack, MD currently recruiting for clinical trials?
Yes, Ibiayi Dagogo-Jack, MD is currently recruiting for 2 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Ibiayi Dagogo-Jack, MD has studied deeply?
Yes, Ibiayi Dagogo-Jack, MD has studied treatments such as Pembrolizumab, Lorlatinib, Alectinib.
What is the best way to schedule an appointment with Ibiayi Dagogo-Jack, MD?
Apply for one of the trials that Ibiayi Dagogo-Jack, MD is conducting.
What is the office address of Ibiayi Dagogo-Jack, MD?
The office of Ibiayi Dagogo-Jack, MD is located at: Massachusetts general Hospital, Boston, Massachusetts 02114 United States. This is the address for their practice at the Massachusetts general Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.